Ignite Creation Date:
2024-05-05 @ 11:30 PM
Last Modification Date:
2024-10-26 @ 10:35 AM
Study NCT ID:
NCT01347203
Status:
COMPLETED
Last Update Posted:
2011-07-07
First Post:
2011-05-02
Brief Title:
A Healthy Volunteer Study to Evaluate for a Single Dose of 4 Different Tablets of DPOC-4088 the Absorption and Elimination From the Body and the Potential Effect on Blood Clotting
Sponsor:
Diakron Pharmaceuticals
Organization:
Diakron Pharmaceuticals
Study Overview
Official Title:
A Randomized Open-label 4-period Crossover Study to Evaluate the Pharmacokinetics PK Pharmacodynamics PD and the PKPD Relationship of DPOC-4088 After Single Oral Dosing of 100 and 200 mg in 2 Prolonged Release Formulations 16 and 20 hr in 12 Healthy Young Male Subjects
Status:
COMPLETED
Status Verified Date:
2011-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This will be a study existing of 4 periods to evaluate for a single dose of 4 different tablets of DPOC-4088 the absorption and elimination from the body and the potential effect on blood clotting The differences between the tablets are the dose 100 or 200 mg and the rate of release of DPOC-4088 from the tablet 16 or 20 hours The allocation of the tablets in each period will be determined by chance but is known upfront
Detailed Description:
This will be a randomized open-label single oral dose study The 4-period crossover study will determine and compare the PK and PD profiles of DPOC-4088 when administered as a single oral dose of 100 mg and 200 mg of DPOC-4088 in two prolonged release formulations 16 and 20 hr in 12 evaluable young healthy male subjects
Each subject in a fasting state will receive each of the 4 treatments A B C and D in a balanced 4-period crossover design Each treatment consists of a single oral dose of 100 mg or 200 mg of DPOC-4088 in either prolonged release formulation 16 or 20 hr Subjects will arrive at the study unit for an overnight fast of at least 10 hrs the evening before each dosing period and remain in the unit for at least 24 hrs after dosing Standard meals will be provided and subjects will receive their first meal after dosing at 4 hrs post-dose Blood samples will be drawn for PK and PD evaluations immediately prior to dosing and at specified time intervals for 48 hrs post-dosing Each dosing period will be separated by at least a 5-day washout period that is preferentially not to exceed 10 days
In healthy young male subjects the safety tolerability and the PK profile of DPOC-4088 will be assessed Additionally this study will assess the PD profile and the relationship of PKPD in terms of the ability of DPOC-4088 to inhibit thrombin activity based on prolongation of aPTT ECT TT and PT
Each subject in a fasting state will receive each of the 4 treatments A B C and D in a balanced 4-period crossover design Each treatment consists of a single oral dose of 100 mg or 200 mg of DPOC-4088 in either prolonged release formulation 16 or 20 hr Subjects will arrive at the study unit for an overnight fast of at least 10 hrs the evening before each dosing period and remain in the unit for at least 24 hrs after dosing Standard meals will be provided and subjects will receive their first meal after dosing at 4 hrs post-dose Blood samples will be drawn for PK and PD evaluations immediately prior to dosing and at specified time intervals for 48 hrs post-dosing Each dosing period will be separated by at least a 5-day washout period that is preferentially not to exceed 10 days
In healthy young male subjects the safety tolerability and the PK profile of DPOC-4088 will be assessed Additionally this study will assess the PD profile and the relationship of PKPD in terms of the ability of DPOC-4088 to inhibit thrombin activity based on prolongation of aPTT ECT TT and PT
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None